Credit Suisse Ag Inhibrx, Inc. Transaction History

Credit Suisse Ag

  • $101 Billion
  • Q1 2024

A detailed history of Credit Suisse Ag transactions in Inhibrx, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 18,561 shares of INBX stock, worth $270,990. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,561
Previous 19,742 5.98%
Holding current value
$270,990
Previous $750,000 13.6%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024
SELL
$32.76 - $39.56 $38,689 - $46,720
-1,181 Reduced 5.98%
18,561 $648,000
Q4 2023

Feb 08, 2024
SELL
$14.5 - $38.0 $45,921 - $120,346
-3,167 Reduced 13.82%
19,742 $750,000
Q3 2023

Nov 13, 2023
SELL
$15.75 - $26.31 $102,280 - $170,857
-6,494 Reduced 22.09%
22,909 $420,000
Q2 2023

Aug 11, 2023
BUY
$16.96 - $27.82 $152,860 - $250,741
9,013 Added 44.2%
29,403 $763,000
Q1 2023

May 10, 2023
BUY
$18.45 - $27.14 $23,505 - $34,576
1,274 Added 6.66%
20,390 $384,000
Q4 2022

Feb 13, 2023
SELL
$20.18 - $33.33 $16,345 - $26,997
-810 Reduced 4.07%
19,116 $471,000
Q3 2022

Nov 10, 2022
BUY
$11.58 - $24.73 $92,246 - $196,999
7,966 Added 66.61%
19,926 $358,000
Q2 2022

Aug 12, 2022
BUY
$8.52 - $25.26 $101,899 - $302,109
11,960 New
11,960 $136,000
Q1 2022

May 16, 2022
SELL
$19.89 - $43.18 $143,605 - $311,759
-7,220 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$26.75 - $46.02 $193,135 - $332,264
7,220 New
7,220 $315,000

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email